Skip to main content

Unassisted use

Probability of successful unassisted radiocephalic AVF use within 1 year, from the 4–6 week ultrasound

Heindel P, et al. Predicting radiocephalic arteriovenous fistula success with machine learning. npj Digit Med. 2022;5:160.

All three inputs come from the duplex ultrasound performed 4–6 weeks after AVF creation.

Flow volume
Access flow volume: the mean of three measurements in the cephalic vein 5 cm above (proximal to) the anastomosis.
Cephalic vein diameter
Outflow (cephalic) vein lumen diameter, measured twice at each of three forearm locations (3 cm above the anastomosis, mid-forearm, and just below the antecubital fossa), averaged into one value.
≥50% luminal stenosis
≥50% narrowing of the lumen anywhere along the access.

Definitions follow the methods of Heindel et al., npj Digit Med 2022.

Model details

Take-home point: following radiocephalic AVF creation, a simplified model-based calculator containing only 4–6 week ultrasound parameters (flow, vein diameter and stenosis) performed better than both the UAB and KDOQI threshold criteria in predicting successful unassisted AVF use by 1 year after RC-AVF creation.

Details: the calculator uses a logistic regression model with lasso variable selection, chosen after assessing multiple machine learning models.

The models were trained and tested on pooled patient-level data from the 2014–2019 international multicenter randomized controlled trials PATENCY-1 and PATENCY-2 (ClinicalTrials.gov NCT02110901 and NCT02414841). These trials prospectively tracked outcomes after new radiocephalic arteriovenous fistula (RC-AVF) creation in 914 patients with advanced chronic kidney disease. The outcome is successful unassisted AVF use within 1 year of RC-AVF creation, defined as 2-needle cannulation for hemodialysis for ≥90 days without a preceding procedural intervention. Routine ultrasounds were performed 4–6 weeks after surgery to assess AVF maturation.

Model building considered these 4–6 week ultrasound measurements and 23 baseline clinical factors, including age, sex, race, smoking status, diabetes, hemodialysis status at the time of AVF creation, AVF location, enrolling-site volume and anesthesia modality. Six modeling strategies were compared: logistic regression, lasso, elastic net, CART, random forest and boosted trees. The lasso model performed as well as much more complex models and retained only three ultrasound variables. It retained no baseline characteristics, which suggests that ultrasound parameters matter most for predicting unassisted use after AVF creation. The model performed better than the Kidney Disease Outcomes Quality Initiative (KDOQI) and University of Alabama at Birmingham (UAB) ultrasound criteria in predicting 1-year unassisted AVF use.

More details are in the open-access publication. The 3-year outcomes from the trial registries are reported here.

Performance in the test set

ROC curve for the lasso model with KDOQI and UAB operating points. Lasso: AUROC 0.794, accuracy 72.5%, sensitivity 66.7%, specificity 77.0%. UAB: accuracy 65.2%, sensitivity 78.2%, specificity 55.0%. KDOQI: accuracy 61.8%, sensitivity 23.1%, specificity 92.0%.

Receiver operating characteristic curve for the lasso model (AUROC 0.794), with the operating points of the KDOQI and UAB ultrasound criteria and a table of accuracy, sensitivity, specificity, PPV and NPV for each.

Calibration plot: observed versus predicted probability of unassisted use by decile, close to the diagonal. Intercept -0.019, slope 1.356.

Calibration: observed proportion with unassisted use against predicted probability, by decile, with a smoothed curve. Calibration intercept −0.019, slope 1.356.

Decision curve analysis: the model has higher net benefit than the KDOQI and UAB criteria and the use-all and use-none strategies across most threshold probabilities.

Decision curve: net benefit across threshold probabilities for the model, the KDOQI and UAB criteria, and the use-all and use-none strategies.